Home › Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
 

Keywords :   


Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints

2015-06-10 14:46:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. & SEOUL, South Korea Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel (etanercept), and SB2, an investigational biosimilar of Remicade (infliximab), met their primary endpoints, demonstrating equivalence to the originator medicine in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: met primary studies phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »